BEAM Q4 2022 Earnings — Beam Therapeutics Inc. Revenue & Financial Results | Market Cap Arena

BEAMBeam Therapeutics Inc.

$3B

Q4 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$20M-60.8% YoY

Gross Profit

-$66M-330.9% margin

Operating Income

-$89M-444.1% margin

Net Income

-$38M-191.4% margin

EPS (Diluted)

$-0.54

QoQ Revenue Growth

+26.8%

Cash Flow

Operating Cash Flow

-$69M

Free Cash Flow

-$77M

Stock-Based Comp.

$22M

Balance Sheet

Total Assets

$1.3B

Total Liabilities

$608M

Stockholders' Equity

$733M

Cash & Equivalents

$233M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$20M	$51M	-60.8%
Gross Profit	-$66M	$109M	-160.7%
Operating Income	-$89M	-$63M	-40.2%
Net Income	-$38M	-$65M	+40.7%